Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Najla Al-Ali.
Leukemia Research | 2013
Vu H. Duong; Jeffrey E. Lancet; Ezzideen Alrawi; Najla Al-Ali; Janelle Perkins; Teresa Field; Pearlie K. Epling-Burnette; Ling Zhang; Alan F. List; Rami S. Komrokji
Azacitidines efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P=0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.
Clinical Lymphoma, Myeloma & Leukemia | 2015
Julio C. Chavez; Samir Dalia; Jose D. Sandoval-Sus; Mohamed A. Kharfan-Dabaja; Najla Al-Ali; Rami S. Komrokji; Eric Padron; Gabriela Corrales-Yepez; Jennifer Rock-Klotz; Javier Pinilla-Ibarz
Patients with chronic lymphocytic leukemia (CLL) have a 2- to 5-fold risk of developing a second malignancy compared with the general population. The incidence of myeloid malignancies, such as acute myeloid leukemia and myelodysplastic syndrome, is increased in CLL and has been linked to previous therapy. In this study, we aim at describing characteristics and determining risk factors for developing second myeloid disorders (SMDs) in patients with CLL. From a total of 1269 patients diagnosed with CLL during the study time period, 30 (2.4%) were found to have an SMD. The majority of SMDs were myelodysplastic syndrome or acute myeloid leukemia (76.7%). The median time from diagnosis of CLL to diagnosis of SMD was 4.47 years. Most patients who developed an SMD had received treatment for their CLL (86%). The median time from treatment of CLL to diagnosis of SMD was 4.19 years. The overall survival of patients with CLL with no second malignancy was significantly longer than those with an SMD (11.9 vs. 7.1 years, P = .001). There was no association between developing SMD and age, gender, expression of CD38, expression of ZAP-70, and unmutated immunoglobulin heavy chain gene status. The risk of developing SMD in our cohort was higher in patients who received fludarabine- or alkylator-based therapy. Our analysis is one of the largest series showing that patients receiving fludarabine or alkylator-based therapies for CLL have a higher risk of developing SMD. Our study also confirms previous reports that prognostic factors in CLL do not increase the risk for development of SMD. Clinicians should understand the leukemogenicity of fludarabine or alkylator-based treatments when considering treatments for patients with CLL.
Blood | 2018
Prithviraj Bose; Aziz Nazha; Rami S. Komrokji; Keyur P. Patel; Sherry Pierce; Najla Al-Ali; Andrew Sochacki; Aaron C. Shaver; Wencai Ma; Xiaoping Su; Naval Daver; Courtney D. DiNardo; Guillermo Garcia-Manero; Sanam Loghavi; Carlos E. Bueso-Ramos; Hagop M. Kantarjian; Mikkael A. Sekeres; Michael R. Savona; Jaroslaw P. Maciejewski; Srdan Verstovsek
TO THE EDITOR: The “unclassifiable” myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U) remain the most poorly characterized among the various subtypes of MDS/MPN.[1][1] Retrospective studies have reported the median survival of patients with MDS/MPN-U to be 21 months from diagnosis[2][2]
Blood | 2016
Rami S. Komrokji; Mikkael A. Sekeres; John Barnard; Najla Al-Ali; Amy E. DeZern; Eric Padron; David Sallman; Jeffrey E. Lancet; Gail J. Roboz; Jaime Fensterl; Guillermo Garcia-Manero; David P. Steensma; Alan F. List
Clinical Lymphoma, Myeloma & Leukemia | 2017
Chetasi Talati; Andrew Kuykendall; Najla Al-Ali; Rami S. Komrokji; Eric Padron; David Sallman; Alan F. List; Kendra Sweet; Martine Extermann; Jeffrey E. Lancet
Clinical Lymphoma, Myeloma & Leukemia | 2017
Megan Melody; David Sallman; Najla Al-Ali; Hanadi Ramadan; Ling Zhang; Eric Padron; Kendra Sweet; Martine Extermann; Alan F. List; Jeffery Lancet; Rami S. Komrokji
Clinical Lymphoma, Myeloma & Leukemia | 2017
Daniel Kerr; Andrew Kuykendall; Chetasi Talati; Najla Al-Ali; David Sallman; Kendra Sweet; Jeffrey E. Lancet; Alan F. List; Eric Padron; Rami S. Komrokji
Blood | 2016
Chetasi Talati; Adam Marsh; Kylie Baggett; Najla Al-Ali; Kendra Sweet; David Sallman; Rami S. Komrokji; Alan F. List; Eric Padron; Jeffrey E. Lancet
Blood | 2016
Kathy L. McGraw; Johnny Nguyen; Najla Al-Ali; Jinming Song; David Sallman; Eric Padron; Jeffrey E. Lancet; Daihui Qin; P.K. Epling-Burnette; Lynn C. Moscinski; Rami S. Komrokji; Alan F. List; Ling Zhang
Blood | 2016
Christa Roe; Najla Al-Ali; Eric Padron; Pearlie K Burnette; Kendra Sweet; David Sallman; Lubomir Sokol; Jeffrey E. Lancet; Alan F. List; Rami S. Komrokji